Keratoendotheliitis Fugax Hereditaria (KEFH)

Scientifically, KEFH is linked to a single letter change in a gene called NLRP3 (this gene makes a protein nicknamed cryopyrin, part of the body’s inflammation? “alarm system” called the NLRP3 inflammasome). The specific change is c.61G>C, which swaps one amino acid for another (p.Asp21His) and makes the inflammasome too easy to switch on, causing flares in the cornea. This variant has been confirmed in Finnish families and also appears at low frequency in other European populations. PubMedScienceDirect

During flares, microscope imaging shows tiny “pseudoguttata” spots on the cornea’s inner layer (the endothelium) and hazy swelling? in the back layers of the cornea. Between attacks, the eye can look normal. PubMedEye Disorders Database

Keratoendotheliitis Fugax Hereditaria—often shortened to KEFH—is a rare, inherited eye condition that causes short, painful “attacks” of corneal inflammation. Affected people usually get unilateral? (one-eye) episodes of redness, light sensitivity?, blurry vision, and corneal swelling that last about 2–5 days, then settle. Over many years, repeated attacks can leave faint central corneal scars in some patients. KEFH is autosomal dominant (it tends to run in families), and modern research links it to a mutation in the NLRP3 gene (cryopyrin), which makes the eye’s innate immune system “too easy to trigger.” NCBIEyeWikiPubMed

KEFH is a genetic?, “on-and-off” inflammation of the inner layer of the cornea (the endothelium) that flares for a few days and then calms down. During a flare?, the clear window of the eye (the cornea) temporarily clouds and swells, so vision goes foggy and lights may look haloed. Pain?, tearing, and redness are common. Between attacks, many people feel normal and see well. After years of attacks, some develop persistent central stromal opacities (light scars) that can mildly reduce vision. KEFH usually starts in childhood or early adulthood, often affects one eye at a time, and tends to improve in middle age (fewer, milder attacks). Triggers often include cold wind and stress. The driving cause is a hyper-reactive NLRP3 inflammasome (a molecular “alarm system” inside immune cells), which explains why the condition is grouped with cryopyrin-associated periodic syndromes (CAPS). EyeWikiScienceDirectPMCPubMed

Many people with KEFH are initially misdiagnosed (often as anterior uveitis/iritis), and it can take years to reach the correct diagnosis?—so recognizing the pattern matters. PubMedFolkhälsan Research

Types

There aren’t official subtypes, but doctors often describe KEFH in useful patterns:

1. By laterality (which eye):

   • Unilateral (most common): one eye at a time.

   • Alternating bilateral?: one eye, then the other on a different day.

   • Simultaneous bilateral (rare): both eyes together. EyeWiki

2. By age pattern:

   • Typical childhood onset? (most begin ~age 6–12, median ~11).

   • Late onset (teen/adult first flare). Flares tend to ease with age. PubMedEye Disorders Database

3. By phase:

   • Acute? attack: red, painful eye; corneal swelling; pseudoguttata; vision blur.

   • Between attacks: quiet eye, sometimes central corneal faint scars after years. PubMed+1

4. By disease burden:

   • Mild?: few flares, no lasting haze.

   • Moderate?: repeated flares with faint central haze.

   • Severe?: many flares, central stromal opacities with mild chronic? blur. PubMed

5. By genetics:

   • Familial (autosomal dominant): typical.

   • Sporadic (de novo): uncommon but reported; genetic testing can help confirm. EyeWiki

Causes

Root biological cause

1. NLRP3 gene mutation (c.61G>C; p.Asp21His): makes cryopyrin overly sensitive; inflammation switches on too easily. PubMedScienceDirect

2. Overactive NLRP3 inflammasome: lowers the threshold to start an eye-inflammation attack. Helda

3. Autosomal-dominant inheritance: one changed copy from a parent is enough to cause the condition. Eye Disorders Database

4. Founder effect in Northern Europe: variant enriched in Finnish/nearby ancestry (still rare overall). PubMed

5. Occasional de novo mutation: new mutation in a child even if parents aren’t affected. EyeWiki

Commonly reported attack triggers (not the cause of the disease, but things that may set off a flare)

6. Cold wind/cold air exposure. PubMedAjo

7. Psychological stress (or shifts in stress). PubMed

8. Lack of sleep/fatigue? (reported). Wiley Online Library

9. Mild viral? illness (reported anecdotally). EyeWiki

10. Ocular micro-trauma? or irritation (e.g., rubbing, environmental grit) may be associated in some reports. ScienceDirect

11. General systemic? immune “priming” (body is more inflamed than usual) can lower the flare threshold. (Inference from NLRP3 biology and CAPS family.) PMC

Less frequent or possible contributors noted in series/reviews

12. Air drafts/dry air (overlaps with “cold air”). Helda

13. Recent minor eye infection? (diagnostic confusion? with infectious keratitis is common; infections per se are not KEFH, but intercurrent infections may confuse/trigger care). Mayo Clinic

14. Misdiagnosed uveitis episodes can delay correct care and allow more attacks (not a cause, but a contributor to burden). PubMed

15. Allergy?-like histamine state (antihistamines sometimes help symptoms; evidence mainly symptomatic). EyeWiki

16. Windy outdoor work/exposure (environmental cold-wind overlap). PubMed

17. Eye surgery/trauma history (rarely discussed; included as potential nonspecific trigger for corneal inflammation in general). ScienceDirect

18. Family history? (isn’t a trigger but predicts risk strongly). Eye Disorders Database

19. Age (attacks more frequent/severe in youth; tend to soften with age). PubMed

20. Unknown factors (many attacks happen without a clear trigger). PubMed

Important note: The gene mutation is the cause; items 6–20 are reported triggers or contributors that may bring on a flare in someone who already has KEFH.

Symptoms

1. Eye pain (often moderate to severe). NCBI

2. Red eye (conjunctival injection). NCBI

3. Blurred vision? (from corneal swelling/haze). EyeWiki

4. Light sensitivity (photophobia?)—bright light hurts. Eye Disorders Database

5. Watering/tearing (lacrimation). NCBI

6. Gritty/foreign-body feeling. NCBI

7. Colored halos around lights (when the cornea is swollen). NCBI

8. Double vision? (diplopia) at times (from blur/halos, not from eye muscles). NCBI

9. Mild headache or “stiff neck” feeling (described in some histories). EyeWiki

10. One-sided nasal stuffiness/runny nose on the same side as the affected eye (reported). EyeWiki

11. Eye becomes very tender to touch (pain worsens with palpation). EyeWiki

12. Temporary drop in vision acuity during attacks. PubMed

13. Mild anterior chamber reaction (tiny inflammatory cells seen by the doctor’s microscope; patients feel it as pain/photophobia). PubMed

14. Between attacks: usually no symptoms, but central corneal haze can leave mild “permanent” blur in older patients with many flares. PubMed

15. Attacks recur (often several times per year), then taper with age. PubMed

Diagnostic tests

A) Physical exam (done in the clinic chair)

1. History pattern check
   The doctor asks about short, repeat flares starting in childhood with pain/redness/blur in one eye that settle within a few days. This pattern strongly suggests KEFH and helps separate it from infections or classic uveitis. PubMed+1

2. Visual acuity (eye chart)
   Measures how much the attack reduces vision and tracks recovery between flares. (Usually returns to baseline unless scarring accumulates.) PubMed

3. Penlight photophobia test
   Bright light hurts because the inflamed cornea is sensitive—this is a simple, quick check consistent with corneal disease. Eye Disorders Database

4. External exam
   Looks for redness, tearing, lid squeezing—the “red painful photophobic eye” pattern that points to the cornea. NCBI

5. Pupil exam
   Ensures there’s no serious nerve problem; also helps rule out other causes of visual loss when the cornea clears. (Usually normal in KEFH.) Eye Disorders Database

B) “Manual” office tests (hands-on or simple tools)

6. Slit-lamp biomicroscopy during a flare
   The key exam: shows corneal edema/haze and pseudoguttata (tiny dark “holes” between endothelial cells), sometimes a mild anterior chamber reaction. Between flares, the eye may look normal or show central stromal opacities from prior attacks. PubMed+1

7. Fluorescein dye + blue light
   Helps confirm the cornea is the source of symptoms and rules out epithelial ulcers that suggest infections (bacterial, herpes, etc.). Mayo Clinic

8. Intraocular pressure (IOP) check
   Usually normal in KEFH but measured to exclude angle-closure glaucoma or steroid-response pressure rise if drops are used. EyeWiki

9. Cotton-wisp corneal sensitivity
   Normal sensitivity supports non-herpetic inflammation; reduced sensitivity leans to herpetic keratitis—a key differential. Mayo Clinic

10. Schirmer tear test / tear breakup time
    Not diagnostic for KEFH itself, but helps rule out dry eye as a cause of irritation or muddled symptoms. (Supportive test.) Mayo Clinic

C) Lab & pathological tests

11. Genetic testing for NLRP3 (targeted variant c.61G>C; p.Asp21His)
    The confirmatory test when the story fits (especially with family history or atypical findings). It proves the diagnosis in uncertain cases. PubMed

12. Inflammatory blood markers (CRP/ESR) during a flare
    Often normal in KEFH (eye-limited), but checking can exclude systemic inflammatory diseases; in CAPS relatives, these can rise, so clinicians sometimes look. PMC

13. Aqueous tap PCR (rare/only if needed)
    If a first attack looks unusual, doctors may test eye fluid to exclude herpes endotheliitis before using strong steroids. (This is uncommon but cautious medicine.) Mayo Clinic

14. Histopathology (very rare; after corneal transplant if ever done)
    Pathology from a corneal “button” has shown inflammatory cell changes consistent with prior flares. This is not routine—only reported in research/exceptional cases. PubMed

D) Electrodiagnostic tests (seldom needed; used to rule out other causes of blurred vision)

15. Visual evoked potential (VEP)
    Not for diagnosis of KEFH; occasionally used if vision remains poor after the cornea clears to confirm the problem isn’t in the optic nerve/brain. (Rare scenario.)
    (Included here because you asked for electrodiagnostic items; most KEFH patients never need this.)

16. Electroretinogram (ERG)
    Similarly, rarely used. It checks retinal function if clinicians suspect another condition hiding behind the corneal symptoms.
    (Again, rarely indicated in typical KEFH.)

E) Imaging tests (very helpful in KEFH)

17. Specular microscopy
    Photographs the corneal endothelium. During a flare it shows pseudoguttata (dark, non-reflective gaps); even between attacks it may show mild cell shape/size changes. This is one of the most informative tests for KEFH. EyeWiki

18. In vivo confocal microscopy (IVCM)
    A higher-resolution “live” microscope that has shown hyper-reflective inflammatory cells in the corneal stroma/endothelium during attacks and helps confirm the characteristic pattern. PubMed

19. Corneal pachymetry (ultrasound or optical)
    Measures thickness, which increases by ~5–14% during a flare and returns to baseline afterward. EyeWiki

20. Anterior segment OCT (AS-OCT)
    Non-contact scan that documents posterior stromal haze/edema and helps track resolution after the attack. Corneal topography may also be used to document changes or rule out other corneal conditions. PubMed

Non-pharmacological treatments

Important: These measures support comfort, safety, and trigger management. They do not replace medical therapy when a flare is active.

1. Cold-avoidance plan
   Purpose: Reduce flares thought to be triggered by cold wind or air.
   Mechanism: Avoids a physical trigger that may perturb corneal homeostasis and NLRP3 activation. Practical tips: wrap-around glasses outdoors; avoid direct AC venting; use a scarf mask in cold weather. ScienceDirect

2. Stress-reduction routine
   Purpose: Lower stress-linked flares.
   Mechanism: Calms autonomic and inflammatory pathways that may prime NLRP3 activation. Examples: paced breathing, short daily mindfulness, light exercise if your ophthalmologist okays it. PMC

3. Moisture-chamber eyewear
   Purpose: Shield the ocular surface from dry, windy environments.
   Mechanism: Reduces evaporation and wind shear that can irritate the corneal surface during recovery.

4. Humidification of rooms
   Purpose: Keep ambient humidity 40–50% to reduce surface dryness and irritation.

5. Screen-time hygiene
   Purpose: Minimize light sensitivity and strain.
   Mechanism: Frequent blink breaks (20-20-20), reduce glare, use night modes during recovery.

6. Sunglasses/photophobia control
   Purpose: Comfort in bright light.
   Mechanism: Filters incoming light; polarized lenses help with halos.

7. Driving/operating machinery pause during a flare
   Purpose: Safety.
   Mechanism: Temporary blurred vision + halos increases risk.

8. Sleep optimization
   Purpose: Recover faster; lower inflammatory tone.
   Mechanism: Sleep supports immune regulation and healing.

9. Trigger diary
   Purpose: Identify personal precipitating factors (cold, stress bursts, long outdoor exposure).
   Mechanism: Pattern recognition → tailored avoidance.

10. Eye protection for dusty tasks
    Purpose: Reduce micro-trauma/irritation.
    Mechanism: Shields cornea from particulate triggers (gardening, sanding).

11. Contact lens holiday during/after attacks
    Purpose: Prevent extra stress on the cornea while it recovers.
    Mechanism: Allows endothelial pump and surface to normalize.

12. Cool compresses (brief, clean)
    Purpose: Comfort for pain/photophobia.
    Mechanism: Transient vasoconstriction → symptom relief. (Avoid pressure on the globe.)

13. Hydration & blink-lubrication habits
    Purpose: Support surface comfort.
    Mechanism: Adequate hydration and conscientious blinking reduce surface dryness that can worsen light sensitivity (supportive only).

14. Workplace adjustments
    Purpose: Reduce exposure (e.g., cold warehouse, direct fan/AC).
    Mechanism: Environmental control.

15. Protective eyewear in sports
    Purpose: Reduce accidental corneal impacts (micro-trauma).

16. Family education
    Purpose: Because KEFH is autosomal dominant, relatives may benefit from awareness and prompt evaluation during first attacks. Eye Disorders Database

17. Early-action plan
    Purpose: Have pre-agreed steps with your eye doctor for the start of a flare (e.g., same-day visit, what to do if clinic is closed).
    Mechanism: Shortens time to appropriate care.

18. Avoid unnecessary topical irritants
    Purpose: Don’t self-medicate with decongestant “get-the-red-out” drops.
    Mechanism: Rebound redness and surface dryness can worsen comfort.

19. Eye-rubbing avoidance
    Purpose: Rubbing can aggravate symptoms and surface trauma.

20. General anti-inflammatory lifestyle
    Purpose: Lower background inflammatory load.
    Mechanism: Regular physical activity (as cleared by your physician), Mediterranean-style diet pattern, and smoking cessation all support systemic immune balance.

Drug treatments

There is no single, proven “curative” drug for KEFH. Management is based on case reports/series and expert opinion; therapy targets symptom relief during attacks and, in select severe/recurrent cases, upstream IL-1/NLRP3 pathways extrapolated from CAPS therapy. Always follow your ophthalmologist’s dosing and taper. EyeWiki

1) Topical corticosteroids (e.g., prednisolone acetate 1%)
Class: Ophthalmic steroid anti-inflammatory.
Dose/time (typical): 1 drop 4×/day during an acute attack for 3–5 days, then taper over several days per clinician direction.
Purpose: Reduce intra-corneal inflammation and endothelial irritation to shorten symptoms.
Mechanism: Broad suppression of cytokine signaling.
Side effects: Elevated intraocular pressure (IOP), delayed healing, cataract with prolonged/repeated use; infection risk if misused. EyeWiki

2) Soft-steroid alternative (e.g., loteprednol 0.5%)
Class: Ester-based topical steroid.
Use: Similar goals as prednisolone; may be chosen for a lower IOP-rise tendency.
Note: Still requires monitoring.

3) Topical NSAID (e.g., ketorolac 0.5%)
Class: Non-steroidal anti-inflammatory.
Dose/time (typical): 1 drop 3–4×/day for a few days in an attack.
Purpose: Pain/light sensitivity relief.
Mechanism: COX inhibition → lower prostaglandins.
Side effects: Stinging on instillation; with prolonged use, rare corneal adverse effects—so keep short and supervised. EyeWiki

4) Oral NSAID (e.g., ibuprofen 400 mg)
Class: Systemic analgesic/anti-inflammatory.
Dose/time (typical adult): 400 mg every 6–8 h with food, short course.
Purpose: Pain control; may help photophobia.
Cautions: Avoid in peptic ulcer disease, kidney disease, or with anticoagulants unless cleared.

5) Oral antihistamine (e.g., cetirizine 10 mg daily)
Class: H1 blocker.
Purpose: May help comfort (sedation can reduce photophobia/tearing) per reports.
Mechanism: Sedative and mild anti-itch effects; does not treat the genetic cause. EyeWiki

6) Hypertonic saline 5% (drops/ointment)
Class: De-edema agent (topical saline).
Dose/time: Drops 4–6×/day and/or ointment at bedtime during recovery.
Purpose: Draws fluid out of the cornea to clear haze faster (supportive).
Cautions: Stinging; not all patients find it helpful.

7) Cycloplegic drops (e.g., cyclopentolate 1%)—select cases
Class: Antimuscarinic.
Dose/time: 1 drop 2–3×/day briefly if ciliary spasm–type pain is prominent.
Purpose: Light sensitivity and ache relief.
Cautions: Blurs near vision; avoid driving after instillation.

8) Lubricating drops/gel (preservative-free preferred during flares)
Class: Ocular surface protectants.
Use: QID or more for comfort; particularly helpful when photophobia is high.
Note: Supportive only.

9) IL-1 receptor antagonist (anakinra) — off-label, specialist use
Class: Targeted anti-inflammatory (biologic).
Dose/time (typical CAPS): 100 mg subcutaneous daily (weight-based in children).
Purpose: In rare, severe/refractory KEFH linked to NLRP3 hyperactivity—especially if there are systemic CAPS-like signs—some clinicians extrapolate from CAPS evidence.
Mechanism: Blocks IL-1 signaling downstream of NLRP3.
Side effects: Injection-site reactions, infection risk; needs systemic specialist oversight. Evidence in KEFH is limited (case-level). PMCScienceDirect

10) IL-1β monoclonal antibody (canakinumab) — off-label, specialist use
Class: Targeted biologic.
Dose/time (common CAPS adult): 150 mg SC every 8 weeks (weight-based variants).
Purpose: Similar rationale as anakinra; not standard for KEFH but biologically plausible in selected severe contexts.
Side effects: Infection risk; cost; requires rheumatology/ophthalmology co-management. Frontiers

What’s not recommended by default: Empiric antivirals or antibiotics unless your clinician suspects an infectious mimic (e.g., HSV endotheliitis). KEFH itself is not an infection.

Dietary, molecular & supportive supplements

Key disclaimer: None of these has direct clinical evidence for KEFH. Think of them as adjuncts for general anti-inflammatory health. Discuss all supplements with your clinician, especially if pregnant, on blood thinners, or with kidney/liver disease.

1. Omega-3 fatty acids (fish oil) — 1–2 g/day EPA+DHA.
   Function/mechanism: Pro-resolving mediators that generally dampen inflammatory signaling.

2. Vitamin D3 — check level; typical 800–2000 IU/day if low.
   Mechanism: Immune modulation; correct deficiency.

3. Vitamin C — 200–500 mg/day.
   Mechanism: Antioxidant support for ocular surface health.

4. Magnesium — 200–400 mg/day (glycinate/citrate).
   Mechanism: Neuromuscular relaxation; may help stress responses.

5. Curcumin (with piperine or as a bioavailable formulation) — 500–1000 mg/day.
   Mechanism: NF-κB and inflammasome-modulating properties in preclinical studies.

6. Quercetin — 250–500 mg/day.
   Mechanism: Flavonoid with antioxidant/anti-inflammatory effects.

7. Resveratrol — 100–200 mg/day.
   Mechanism: Sirtuin-linked anti-inflammatory signaling.

8. N-acetylcysteine (NAC) — 600 mg 1–2×/day.
   Mechanism: Glutathione precursor; antioxidant.

9. Lutein + Zeaxanthin — per label (often 10 mg/2 mg daily).
   Mechanism: Ocular antioxidants; general retinal health.

10. Coenzyme Q10 — 100–200 mg/day with fat.
    Mechanism: Mitochondrial antioxidant.

11. Green tea extract (EGCG) — standardized dose per label.
    Mechanism: Polyphenol anti-inflammatory properties.

12. Probiotics — daily, multi-strain.
    Mechanism: Gut-immune crosstalk; foundational support.

13. Zinc — 10–25 mg/day (short term unless deficient).
    Mechanism: Immune enzyme cofactor; avoid excess.

14. Saffron extract — per label.
    Mechanism: Antioxidant; small ocular studies in other contexts.

15. Melatonin (evening, 0.5–3 mg)
    Mechanism: Sleep regulation; sleep supports immune balance.

Regenerative / stem-cell” drugs

Reality check: For KEFH, there is no approved “immune reset” or regenerative therapy. Because KEFH stems from NLRP3/IL-1 overactivation, the most biologically targeted choices—anakinra and canakinumab—come from CAPS care and remain off-label for KEFH (see Drug #9–10 above). Stem-cell or endothelial-cell therapies are being developed for other corneal endothelial diseases (like bullous keratopathy or Fuchs), and show promise, but they’re not designed for KEFH, where the endothelium is mostly normal between attacks. If the eye develops fixed scarring, surgery—not cell therapy—may be considered. New England Journal of MedicineScienceDirectPMC

A candid list of what clinicians may discuss in complex cases (specialist only):

1. Anakinra (IL-1 receptor antagonist) — see Drug #9 above.

2. Canakinumab (anti-IL-1β) — see Drug #10 above.

3. Other NLRP3-pathway ideas (research stage) — small-molecule NLRP3 inhibitors are being studied outside ophthalmology; no KEFH trials yet. PMC

4. Cultured human corneal endothelial cell (CEC) injection — viable for endothelial failure (not KEFH); early trials/long-term cohorts show safety/efficacy in other diseases. New England Journal of MedicineScienceDirect

5. ROCK-inhibitor–assisted CEC therapy — investigational for endothelial dysfunction; not a KEFH treatment. Lippincott Journals

6. iPSC-derived CECs — first-in-human studies are emerging for endothelial disease, not KEFH. Cell

Surgeries

Most KEFH patients never need surgery. Procedures are reserved for rare cases with persistent, visually significant central stromal scarring after years of attacks.

1. Phototherapeutic keratectomy (PTK)
   What it is: An excimer laser gently polishes the front corneal layers to reduce superficial scars/irregularities.
   Why: If the opacity is superficial and disrupts vision/glare.
   Notes: Recurrence of scars is possible over time; careful selection is vital. EyeWiki

2. Deep anterior lamellar keratoplasty (DALK)
   What: Surgeons replace the corneal stroma while preserving Descemet’s membrane and endothelium.
   Why: Deeper stromal scarring without endothelial failure.
   Notes: Lower rejection risk than full-thickness grafts.

3. Penetrating keratoplasty (PK)
   What: Full-thickness corneal transplant.
   Why: Extensive scarring when other options aren’t suitable.
   Notes: Highest rejection/astigmatism risk; reserved for selected cases.

4. Descemet membrane endothelial keratoplasty (DMEK)
   What: Replaces the endothelium.
   Why: Generally not a KEFH operation (the endothelium is usually fine between attacks); considered only if independent endothelial failure occurs from another cause.

5. Photorefractive “surface smoothing” adjuncts
   What: Customized laser smoothing for glare/irregularity in select shallow scars, sometimes after PTK assessment.
   Why: Improve optics when opacity is very superficial. PubMed

Prevention strategies

1. Protect from cold wind (wrap-around glasses, scarf). ScienceDirect

2. Manage stress (daily micro-practices). PMC

3. Set an early-flare plan with your ophthalmologist (same-day access).

4. Avoid eye rubbing.

5. Use moisture-chamber eyewear in harsh environments.

6. Humidify indoor air.

7. Pause contact lenses during/after flares.

8. Keep protective eyewear for dusty/impact-risk tasks.

9. Educate family members (autosomal dominant). Eye Disorders Database

10. Maintain general health (sleep, activity, balanced diet) to support immune stability.

When to see a doctor

Call your eye doctor promptly if you have any of the following:

• A new attack (especially if it’s your first or worse than usual).

• Severe pain, marked light sensitivity, or rapidly worsening blur.

• Symptoms not improving within 2–3 days, or blur persisting beyond 2–3 weeks.

• Both eyes affected at once, or attacks >3–4 times/year.

• Systemic symptoms suggestive of CAPS (fevers, rash, joint pains) — you may need genetics/rheumatology input. NCBI

What to eat and what to avoid

What to favor

• Mediterranean-style pattern: vegetables, fruits, legumes, whole grains, nuts, olive oil, fish (omega-3s).

• Hydration: regular water intake supports surface comfort.

• Protein: helps tissue repair (fish, poultry, beans, dairy if tolerated).

• Micronutrients: foods rich in vitamin C (citrus, peppers), vitamin D (fortified dairy/fish), and lutein/zeaxanthin (leafy greens).

What to limit

• Ultra-processed, high-sugar foods that can amplify systemic inflammation.

• Very salty meals that may worsen temporary fluid retention.

• Excess alcohol, which can disturb sleep and immunity.

• Any food you personally notice precedes flares (use your trigger diary).

Frequently asked questions (FAQs)

1) Is KEFH contagious?
No. It’s genetic and inflammatory, not infectious.

2) Will every family member get it?
KEFH is autosomal dominant, so each child of an affected parent has about a 50% chance to inherit the variant—but actual expression varies. Genetic counseling can help. Eye Disorders Database

3) How long do attacks last?
Most flares resolve in 2–5 days; vision blur may linger weeks as the cornea clears. PubMed

4) What starts an attack?
Often cold wind or stress, but triggers differ; some attacks occur without any obvious reason. Keep a diary. ScienceDirect

5) Can it cause permanent damage?
Many patients recover fully between attacks; however, repeated flares can leave central stromal opacities in some people. NCBI

6) Are steroids safe for every attack?
Short courses can help, but they must be supervised due to IOP rise and other risks. Never self-start steroids without guidance. EyeWiki

7) Do antivirals help?
Not for KEFH itself. Antivirals are used only if your doctor suspects herpetic endotheliitis, a different condition.

8) Are biologics (anakinra/canakinumab) a cure?
No cure. In rare, severe cases with systemic CAPS features, specialists may consider them off-label; evidence in KEFH is limited. ScienceDirect

9) Can supplements stop attacks?
No supplement is proven to prevent KEFH flares. Some may support general anti-inflammatory health, but they don’t replace medical care.

10) Will I need surgery?
Unlikely. Surgery is only for persistent, vision-limiting scars, and the choice depends on scar depth (PTK vs. lamellar vs. PK). EyeWiki

11) Can I wear contact lenses?
Yes, between attacks if your doctor approves. Avoid contacts during flares and early recovery.

12) Is KEFH only in Finland?
It was first recognized in Finland, but NLRP3-linked KEFH has also been identified in non-Finnish Europeans. PubMed

13) Why was I told it’s “uveitis” or “HSV” before?
KEFH can mimic these conditions. Diagnostic delays/mislabels are reported, which is why history + exam + (sometimes) genetics matter. Ajo

14) Can children have KEFH?
Yes—childhood onset is common; families should have a plan for prompt evaluation in early attacks. EyeWiki

15) What’s the outlook?
Generally good: attacks are self-limited and often lessen with age. Long-term scarring can occur in some; staying on top of trigger control and early treatment helps. Ajo

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 09, 2025.